Maximus review

Maximus advertises tirzepatide from $249.99 a month on a two-month plan. That commitment belongs beside the price. Ask for the full amount due, the shipment schedule and whether the same rate applies to your prescribed dose before treating it as a monthly budget.

FDA issued warning letter 730095 to Maximus Health, Inc. dba Maximus on June 8, 2026, after reviewing maximustribe.com in May. It cited claims implying clinical evaluation of the compounded products and references to FDA-approved pharmacies. FDA explained that it does not grant that approval designation to compounding pharmacies.

This dated letter concerns the marketing identified in that review. It should not be interpreted as evidence that every current prescription is defective or that every later website statement is unchanged. A subsequent closeout or FDA acceptance of corrective action was not established in this source check.

The catalog also lists products including Wegovy, Ozempic, Mounjaro and Zepbound. Their presence does not mean a compounded-plan headline covers a brand prescription. Obtain a product-specific total and clarify whether medication is included, especially if using an insurance or manufacturer payment route.

Maximus says it has no membership fee and includes priority shipping. It describes clinician-led treatment, but the reviewed homepage does not establish the individual dispensing pharmacy or complete cancellation rules for the selected weight-loss offer.

The useful comparison is the cost of the same medication and term, with the same included follow-up. Request the renewal amount and what happens to unused supply if treatment changes. Catalog breadth alone does not tell you which medication is clinically suitable or available in your state.